---
schema_version: "secwatch.filing_event.v1"
accession: "0001485003-22-000167"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2022-12-23T23:59:59+00:00"
generated_at: "2026-06-20T23:18:07.344542+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sesen Bio terminates license agreement with Qilu Pharma; pays $1.4M termination fee

## Summary
- Terminated exclusive license agreement with Qilu Pharmaceutical for Vicineum in Greater China.
- One-time aggregate payment of $1,400,000 to Qilu ($1.2M termination fee + $200K contingent).
- All rights to Vicineum in China, Hong Kong, Macau, and Taiwan revert to Sesen.
- Sesen retains global rights to Vicineum and is exploring strategic alternatives with a financial advisor.

## SEC filing metadata
- accession: 0001485003-22-000167
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2022-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000148500322000167/0001485003-22-000167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000148500322000167/sesn-20221223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001485003-22-000167
- JSON: https://secwatch.observer/filing/0001485003-22-000167.json
- Plain text: https://secwatch.observer/filing/0001485003-22-000167.txt

## Key facts
- Material Agreements
  Carisma Therapeutics Inc. terminated Exclusive License Agreement with Qilu Pharmaceutical Co., Ltd. valued at $1,400,000 (effective 2022-12-23).
  - Action: termination
  - Agreement: license
  - Counterparty: Qilu Pharmaceutical Co., Ltd.
  - Value: $1,400,000
  - Effective: 2022-12-23
  source text: On December 23, 2022, Sesen Bio, Inc. (“Sesen”) and Viventia Bio, Inc., a wholly-owned subsidiary of Sesen (“Viventia,” and together with Sesen, the “Company”), terminated the Exclusive License Agreement (the “License Agreement”) dated July 30, 2020 by and between Sesen, Viventia, and Qilu Pharmaceutical Co., Ltd. (“Qilu”), as well as other related agreements between the Company and Qilu
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000148500322000167/0001485003-22-000167-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.